Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Адъювантная эндокринотерапия постменопаузальных больных раком молочной железы
Адъювантная эндокринотерапия постменопаузальных больных раком молочной железы
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment. Lancet 1896; 2: 104–7, 162–5.
2. Marshall F, Jolly W. The ovary as an organ of internal secretion. Phil Trans R Soc 1906; 198: 99–141.
3. Jensen EV, Desombre ER, Hurst DJ et al. Estrogen-receptor interactions in target tissues. Arch Anat Microsc Morphol Exp 1967; 56: 547–69.
4. Brueggemeier RW. Aromatase inhibitors: new endocrine treatment of breast cancer. Semin Reprod Med 2004; 22: 31–43.
5. Santen RJ, Samojlik E, Lipton A et al. Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. Cancer 1977; 39: 2948–58.
6. Santen RJ, Santner S, Davis B et al. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab 1978; 47: 1257–65.
7. Brodie AM, Brodie HJ, Romanoff L et al. Inhibition of estrogen biosynthesis and regression of mammary tumors by aromatase inhibitors. Adv Exp Med Biol 1981; 138: 179–90.
8. Dowsett M, Coombes RC. Second generation aromatase inhibitor–4-hydroxyandrostenedione. Breast Cancer Res Treat 1994; 30: 81–7.
9. Gazet JC, Coombes RC, Ford HT et al. Assessment of the effect of pretreatment with neoadjuvant therapy on primary breast cancer. Br J Cancer 1996; 73: 758–62.
10. Campos SM. Aromatase inhibitors for breast cancer in postmenopausal women. Oncologist 2004; 9: 126–36.
11. Buzdar A, Howell A. Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. Clin Cancer Res 2001; 7: 2620–35.
12. Coombes RC, Hall E, Gibson LJ et al. Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081–92.
2. Marshall F, Jolly W. The ovary as an organ of internal secretion. Phil Trans R Soc 1906; 198: 99–141.
3. Jensen EV, Desombre ER, Hurst DJ et al. Estrogen-receptor interactions in target tissues. Arch Anat Microsc Morphol Exp 1967; 56: 547–69.
4. Brueggemeier RW. Aromatase inhibitors: new endocrine treatment of breast cancer. Semin Reprod Med 2004; 22: 31–43.
5. Santen RJ, Samojlik E, Lipton A et al. Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. Cancer 1977; 39: 2948–58.
6. Santen RJ, Santner S, Davis B et al. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab 1978; 47: 1257–65.
7. Brodie AM, Brodie HJ, Romanoff L et al. Inhibition of estrogen biosynthesis and regression of mammary tumors by aromatase inhibitors. Adv Exp Med Biol 1981; 138: 179–90.
8. Dowsett M, Coombes RC. Second generation aromatase inhibitor–4-hydroxyandrostenedione. Breast Cancer Res Treat 1994; 30: 81–7.
9. Gazet JC, Coombes RC, Ford HT et al. Assessment of the effect of pretreatment with neoadjuvant therapy on primary breast cancer. Br J Cancer 1996; 73: 758–62.
10. Campos SM. Aromatase inhibitors for breast cancer in postmenopausal women. Oncologist 2004; 9: 126–36.
11. Buzdar A, Howell A. Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. Clin Cancer Res 2001; 7: 2620–35.
12. Coombes RC, Hall E, Gibson LJ et al. Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081–92.
Авторы
В.Ф.Семиглазов1, В.В.Семиглазов2
НИИ онкологии им. проф. Н.Н.Петрова, Санкт-Петербург, Санкт-Петербургский Государственный медицинский университет им. акад. И.П.Павлова
НИИ онкологии им. проф. Н.Н.Петрова, Санкт-Петербург, Санкт-Петербургский Государственный медицинский университет им. акад. И.П.Павлова
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.